These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 28039358)

  • 1. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
    Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
    Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
    Yoshida A; Lee EK; Diehl JA
    Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
    Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
    Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
    Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
    Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
    Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
    Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib-induced autophagy and senescence in gastric cancer cells.
    Valenzuela CA; Vargas L; Martinez V; Bravo S; Brown NE
    Exp Cell Res; 2017 Nov; 360(2):390-396. PubMed ID: 28947133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
    Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
    Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
    Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
    Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity.
    Wang B; Varela-Eirin M; Brandenburg SM; Hernandez-Segura A; van Vliet T; Jongbloed EM; Wilting SM; Ohtani N; Jager A; Demaria M
    EMBO J; 2022 Mar; 41(6):e108946. PubMed ID: 34985783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
    Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
    Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
    Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.
    Klein ME; Dickson MA; Antonescu C; Qin LX; Dooley SJ; Barlas A; Manova K; Schwartz GK; Crago AM; Singer S; Koff A; Tap WD
    Oncogene; 2018 Sep; 37(37):5066-5078. PubMed ID: 29789718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
    Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
    J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
    Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
    Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.